NINLARO

This brand name is authorized in Austria, Brazil, Canada, Cyprus, Estonia, Finland, France, Hong Kong, Croatia, Ireland, Israel, Japan, Lithuania, Netherlands, Poland, Romania, Singapore, Turkey, United Kingdom, United States, South Africa

Active ingredients

The drug NINLARO contains one active pharmaceutical ingredient (API):

1 Ixazomib UNII 46CWK97Z3K - IXAZOMIB CITRATE

Ixazomib is an oral, highly selective and reversible proteasome inhibitor. Ixazomib preferentially binds and inhibits the chymotrypsin-like activity of the beta 5 subunit of the 20S proteasome. Ixazomib induced apoptosis of several tumour cell types in vitro. In vivo, ixazomib demonstrated antitumour activity in various tumour xenograft models, including models of multiple myeloma. Read about Ixazomib

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
NINLARO Hard capsule	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01XG03		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XG Proteasome inhibitors
Discover more medicines within L01XG03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 501118050029202, 501118050029302, 501118050029402
Country: CA	Health Products and Food Branch	Identifier(s): 02456796, 02456818, 02456826
Country: EE	Ravimiamet	Identifier(s): 1715037, 1734140, 1734162, 1849923
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 183869, 392242, 506187
Country: FR	Base de données publique des médicaments	Identifier(s): 66833683, 69537091, 69663414
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 340205, 340211, 340215, 392458, 392460, 392462
Country: HK	Department of Health Drug Office	Identifier(s): 65568, 65569, 65570
Country: IE	Health Products Regulatory Authority	Identifier(s): 88957, 88958, 88959
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 7816, 7817, 7818
Country: JP	医薬品医療機器総合機構	Identifier(s): 4291049M1024, 4291049M2020, 4291049M3027
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1081722, 1081723, 1081724
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 139629, 139637, 139645
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100381826, 100381832, 100381849
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W63372001, W63373001, W63374001
Country: SG	Health Sciences Authority	Identifier(s): 15162P, 15163P, 15164P
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8699456150036, 8699456150043, 8699456150050
Country: US	FDA, National Drug Code	Identifier(s): 63020-078, 63020-079, 63020-080, 63020-230, 63020-390, 63020-400
Country: ZA	Health Products Regulatory Authority	Identifier(s): 51/26/0956, 51/26/0957, 51/26/0958